{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-ZIWDALNK/4e5cfb99-55cf-478a-919f-d96efb0b5128/PDF","dcterms:extent":"4225 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-ZIWDALNK/d6da8f93-0be8-463c-b04c-bc588417d1e9/TEXT","dcterms:extent":"34 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-ZIWDALNK","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2022","dc:creator":["Čebron Lipovec, Nanča","Kos, Mitja","Prelesnik, Sara"],"dc:format":[{"@xml:lang":"sl","#text":"številka:3"},{"@xml:lang":"sl","#text":"letnik:73"},{"@xml:lang":"sl","#text":"str. 199-209"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:115498755","URN:URN:NBN:SI:doc-ZIWDALNK"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"Farmakovigilanca"},{"@xml:lang":"sl","#text":"farmakovigilančni ukrep"},{"@xml:lang":"sl","#text":"Nosečnost"},{"@xml:lang":"sl","#text":"retinoidi"},{"@xml:lang":"sl","#text":"teratogenost"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Ozaveščenost pacientk, farmacevtov in predpisovalcev o farmakovigilančnih ukrepih za varno uporabo retinoidov| Awareness of pharmacovigilance measures for safe use of retinoids among female patients, pharmacists and prescribers|"},"dc:description":[{"@xml:lang":"sl","#text":"Retinoids are compounds derived from vitamin A. They are used in the treatment of many dermatological conditions such as severe acne, eczema and psoriasis, and for certain cancers. Due to teratogenicity, the usage during pregnancy is contraindicated. As usage during pregnancy and cases of congenital malformations continue to occur, the European Medicines Agency implemented a pregnancy prevention programme. To determine patients' and healthcare professionals' awareness of teratogenic potential and their adherence to risk minimisation measures, an international study in eight European countries was conducted. This article represents results for Slovenia compared to mean data for eight European countries. The study has shown high awareness of teratogenic potential among Slovenian patients and healthcare professionals, while on the other hand, prevention measures and the usage of educational material are not fully incorporated in daily clinical practice"},{"@xml:lang":"sl","#text":"Retinoidi so derivati vitamina A, ki jih uporabljamo za zdravljenje kožnih bolezni, kot so hude akne, ekcemi, luskavica, psoriaza, in za zdravljenje nekaterih oblik raka. Zaradi teratogenosti je njihova uporaba med nosečnostjo kontraindicirana, vendar se uporaba med nosečnostjo kot tudi primeri prirojenih okvar ploda v klinični praksi še pojavljajo. Evropska agencija za zdravila je zato razvila farmakovigilančni program za preprečevanje nosečnosti pri uporabnicah retinoidov. V mednarodni raziskavi v osmih evropskih državah smo ovrednotili, v kolikšni meri se pacienti in zdravstveni delavci zavedajo tveganja uporabe retinoidov pri ženskah v rodni dobi ter v kolikšni meri poznajo in izvajajo ukrepe farmakovigilančnega programa. V članku predstavljamo rezultate za Slovenijo v primerjavi s povprečjem vseh osmih evropskih držav. Rezultati kažejo, da je v Sloveniji ozaveščenost o teratogenosti tako med zdravstvenimi delavci kot med pacientkami visoka, a sta uporaba informativnih gradiv in izvajanje preventivnih ukrepov za preprečevanje nosečnosti le delno vpeljana v vsakodnevno klinično prakso"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-ZIWDALNK","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-ZIWDALNK"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-ZIWDALNK/4e5cfb99-55cf-478a-919f-d96efb0b5128/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-ZIWDALNK/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-ZIWDALNK"}}}}